The strengths of our study include the utilisation of a monoclonal UGT2B17 antibody with no cross-reactivity with other UGT enzymes, a well-characterised PCa patient cohort with detailed clinical and pathological data available from prostatectomy specimens, significant follow-up time (>15 years) to assess clinical outcomes in localised disease, measurement of steroid hormones by gold-standard mass spectrometry and supporting data from independent data sets. This evidence concerns the gene SLC35A2 and posterior cortical atrophy.